Georgina V. Long

Also affiliated with Melanoma Institute Australia

Immunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

25.0Author DataRank

Indexed papers

11in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 11 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

Cell(2018)10.1016/j.cell.2018.02.052

Top 2%

8.1DataRank

Top 2%3980 citations

Katherine A. Hoadley, Laila M. Poisson, Alexander J. Lazar, Andrew D. Cherniack, Albert J. Kovatich +866 more

Papers

Driven by 48 papers — median percentile 96. Top paper: “Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma”.

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

New England Journal of Medicine(2019)10.1056/nejmoa1910836

N/A

14.8DataRank · unranked

3741 citations

Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Christopher D. Lao +26 more

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

Cell(2018)10.1016/j.cell.2018.02.052

Top 2%

8.1DataRank

Top 2%3980 citations

Katherine A. Hoadley, Laila M. Poisson, Alexander J. Lazar, Andrew D. Cherniack, Albert J. Kovatich +866 more

Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics

Cell(2018)10.1016/j.cell.2018.03.033

Top 3%

6.4DataRank

Top 3%447 citations

Matthew H. Bailey, Hoifung Poon, Vesteinn Thorsson, Antonio Colaprico, Andreas Bender +883 more

Pan-cancer analysis of whole genomes

Nature(2020)10.1038/s41586-020-1969-6

Top 3%

5.9DataRank

Top 3%3307 citations

Lauri A. Aaltonen, Federico Abascal, Adam Abeshouse, Hiroyuki Aburatani, David J. Adams +1244 more

Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

Cell Reports(2018)10.1016/j.celrep.2018.03.046

N/A

5.5DataRank · unranked

186 citations

Francisco Sanchez-Vega, Konnor C. La, Joshua Armenia, Walid K. Chatila, Augustin Luna +869 more

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study

The Lancet Oncology(2021)10.1016/s1470-2045(20)30726-9

N/A

4.9DataRank · unranked

94 citations

Jennifer Wiggins, Broderick C. Corless, Georgina V. Long, Keith T. Flaherty, Dirk Schadendorf +12 more

Analyses of non-coding somatic drivers in 2,658 cancer whole genomes

Nature(2020)10.1038/s41586-020-1965-x

Top 5%

4.6DataRank

Top 5%668 citations

Federico Abascal, Jeremiah A. Wala, Ofer Shapira, Grace Tiao, Henrik Hornshøj +1240 more

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

European Journal of Cancer(2020)10.1016/j.ejca.2020.11.010

N/A

3.9DataRank · unranked

100 citations

Wen-Jen Hwu, Omid Hamid, Antoni Ribas, Jeffrey S. Weber, Adil Daud +18 more

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆

Annals of Oncology(2020)10.1016/j.annonc.2020.04.471

N/A

3.5DataRank · unranked

110 citations

Alexander N. Shoushtari, D Chauhan, David Palmieri, Belinda Lee, Maartje W. Rohaan +20 more

A multicenter characterization of hepatitis associated with immune checkpoint inhibitors

OncoImmunology(2021)10.1080/2162402x.2021.1875639

N/A

2.2DataRank · unranked

63 citations

Ben McGuigan, Sunandana Chandra, Sarah E. Fenton, Akansha Chowdhary, Lucy Boyce Kennedy +14 more

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

New England Journal of Medicine(2015)10.1056/nejmoa1504030

N/A

1.3DataRank · unranked

8085 citations

Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C. Lance Cowey, Christopher D. Lao +35 more

Oncogenic Signaling Pathways in The Cancer Genome Atlas

Cell(2018)10.1016/j.cell.2018.03.035

N/A

1.2DataRank · unranked

3322 citations

Marco Mina, Joshua Armenia, Walid K. Chatila, Augustin Luna, Konnor C. La +891 more

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

New England Journal of Medicine(2014)10.1056/nejmoa1406037

N/A

1.1DataRank · unranked

1883 citations

Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, James Larkin +30 more

Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

JAMA Oncology(2021)10.1001/jamaoncol.2021.0051

N/A

0.832DataRank · unranked

256 citations

Rebecca Johnson, Aleigha Lawless, Prachi Bhave, Amelia Sawyers, Maya Dimitrova +15 more

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Nature(2022)10.1038/s41586-022-04833-8

N/A

0.731DataRank · unranked

130 citations

Michael G. White, Miles C. Andrews, Manoj Chelvanambi, Russell G. Witt, Joseph R. Daniele +60 more

Anatomic position determines oncogenic specificity in melanoma

Nature(2022)10.1038/s41586-022-04584-6

N/A

0.694DataRank · unranked

101 citations

Miranda V. Hunter, Nelly M. Cruz, Arianna Baggiolini, Mohita Tagore, Yilun Ma +35 more

Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

Journal of Clinical Oncology(2024)10.1200/jco.23.01020

N/A

0.690DataRank · unranked

16 citations

Isabel Li, Mary‐Ann El Sharouni, J. M. Gardner, Aikaterini Dedeilia, Sydney Ch’ng +17 more

Multi-Trait Genetic Analysis Identifies Autoimmune Loci Associated with Cutaneous Melanoma

Journal of Investigative Dermatology(2021)10.1016/j.jid.2021.08.449

N/A

0.683DataRank · unranked

24 citations

Stuart MacGregor, D. Timothy Bishop, Jianxin Shi, Jiyuan An, Jue‐Sheng Ong +72 more

Tumour gene expression signature in primary melanoma predicts long-term outcomes

Nature Communications(2021)10.1038/s41467-021-21207-2

N/A

0.644DataRank · unranked

72 citations

Dominique‐Laurent Couturier, Jérémie Nsengimana, Nuno A. Fonseca, Matthew Wongchenko, Yibing Yan +21 more

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2581

N/A

0.636DataRank · unranked

17 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more

Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047

Journal of Clinical Oncology(2025)10.1200/jco.24.01124

N/A

0.633DataRank · unranked

67 citations

F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala +14 more

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-003066

N/A

0.628DataRank · unranked

65 citations

Allison Betof Warner, Farzana Y. Zaman, Andrew Haydon, Prachi Bhave, Anna K. Dewan +20 more

Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials

Clinical Cancer Research(2019)10.1158/1078-0432.ccr-18-4011

N/A

0.546DataRank · unranked

37 citations

Annie Tasker, Inês Pires da Silva, Camelia Quek, Marcel Batten, Angela Ferguson +10 more

Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2661

N/A

0.542DataRank · unranked

36 citations

Ashley V. Menk, Dayana B. Rivadeneira, Ryan C. Augustin, Mingchu Xu, Jun Li +47 more

Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma

Annals of Oncology(2020)10.1016/j.annonc.2020.07.016

N/A

0.538DataRank · unranked

35 citations

Chandra Mani Adhikari, Serigne Lo, Robert V. Rawson, Rodabe N. Amaria, Alexander M. Menzies +16 more

A brave new framework for glioma drug development

The Lancet Oncology(2024)10.1016/s1470-2045(24)00190-6

N/A

0.494DataRank · unranked

26 citations

Philipp Karschnia, Karisa C. Schreck, Marjolein Geurts, Timothy F. Cloughesy, Jason T. Huse +34 more

Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation

European Journal of Cancer(2023)10.1016/j.ejca.2023.01.016

N/A

0.483DataRank · unranked

24 citations

Laetitia Da Meda, Ines Pires da Silva, Wen Xu, Giovanni Grignani, Alexander M. Menzies +11 more

Two decades of advances in clinical oncology — lessons learned and future directions

Nature Reviews Clinical Oncology(2024)10.1038/s41571-024-00945-4

N/A

0.477DataRank · unranked

23 citations

Christopher M. Booth, Éduardo Bruera, Markus W. Büchler, Alexander Drilon, Terry J. Fry +14 more

Uncovering the complex relationship between balding, testosterone and skin cancers in men

Nature Communications(2023)10.1038/s41467-023-41231-8

N/A

0.449DataRank · unranked

19 citations

Mathias Seviiri, Jean Claude Dusingize, Yeda Wu, Xikun Han, Jianxin Shi +17 more

Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker

Cancer Medicine(2020)10.1002/cam4.3474

N/A

0.425DataRank · unranked

16 citations

Fernando C. L. Carapeto, Aron Y. Joon, Lauren E. Haydu, Huiqin Chen, Fuchenchu Wang +13 more

Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders

JAMA Network Open(2025)10.1001/jamanetworkopen.2025.13727

N/A

0.425DataRank · unranked

16 citations

Marc Machaalani, Razane El Hajj Chehade, Amin H. Nassar, Rashad Nawfal, Michael P. Manos +20 more

Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia

Annals of Oncology(2023)10.1016/j.annonc.2023.06.007

N/A

0.396DataRank · unranked

13 citations

Joshua W.D. Tobin, Yongwoo David Seo, Georgina Gener‐Ricos, Emily Z. Keung, Elizabeth M. Burton +28 more

Anatomic position determines oncogenic specificity in melanoma

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.11.14.383083

N/A

0.396DataRank · unranked

13 citations

Miranda V. Hunter, Nelly M. Cruz, Arianna Baggiolini, Mohita Tagore, Yilun Ma +35 more

Multiplex melanoma families are enriched for polygenic risk

Human Molecular Genetics(2020)10.1093/hmg/ddaa156

N/A

0.373DataRank · unranked

11 citations

Lauren G. Aoude, David L Duffy, Georgina V. Long, Peter A. Johansson, Antonia L. Pritchard +34 more

Germline variants are associated with increased primary melanoma tumor thickness at diagnosis

Human Molecular Genetics(2020)10.1093/hmg/ddaa222

N/A

0.350DataRank · unranked

6 citations

Stuart MacGregor, Mark M. Iles, Richard A. Scolyer, Anne E. Cust, Nicholas K. Hayward +15 more

Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort

Annals of Oncology(2025)10.1016/j.annonc.2025.10.018

N/A

0.345DataRank · unranked

9 citations

Richard A. Scolyer, Elizabeth M. Burton, Klaus J. Busam, Kuang Yu Chen, Ashley Cimino‐Mathews +18 more

Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting

Journal of Translational Medicine(2022)10.1186/s12967-022-03613-2

N/A

0.312DataRank · unranked

7 citations

Richard A. Scolyer, D. Timothy Bishop, Julia Newton‐Bishop, Mark M. Iles, Serigne Lo +14 more

Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9591

N/A

0.292DataRank · unranked

6 citations

Aleigha Lawless, Rachel Woodford, Faisal Fa’ak, Asha Tipirneni, James R. Patrinely +11 more

Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0987

N/A

0.269DataRank · unranked

5 citations

Mohammed Milhem, Christopher Hoimes, Asim Amin, Cristopher Lao, Robert M. Conry +17 more

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9523

N/A

0.259DataRank · unranked

4 citations

Christopher P. Vellano, Miles C. Andrews, Russell G. Witt, Manoj Chelvanambi, Jennifer L. McQuade +15 more

A tailored approach to horizon scanning for cancer medicines

Journal of Cancer Policy(2023)10.1016/j.jcpo.2023.100441

N/A

0.241DataRank · unranked

4 citations

Yat Hang To, Marliese Alexander, Karen Trapani, Paolo A. Ascierto, Sophy Athan +28 more

Author Correction: Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis

Communications Biology(2022)10.1038/s42003-022-03769-z

N/A

0.165DataRank · unranked

2 citations

Lars Feuerbach, Chen Hong, David Mas-Ponte, Randi Istrup Pedersen, PCAWG Drivers and Functional Interpretation Group +1255 more

Author Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower

Nature Communications(2022)10.1038/s41467-022-32343-8

N/A

0DataRank · unranked

0 citations

PCAWG Drivers and Functional Interpretation Working Group, Federico Abascal, Samirkumar B. Amin, Pratiti Bandopadhayay, Rameen Beroukhim +1242 more

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

(2023)10.1158/1078-0432.c.6533110

Top 100%

0DataRank

Top 100%0 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more

Data from Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors

(2023)10.1158/1078-0432.c.6530489.v1

N/A

0DataRank · unranked

0 citations

Karen A. Autio, Talia Golan, Konstantin Dobrenkov, Elliot Chartash, Qiusheng Chen +3 more

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

(2023)10.1158/1078-0432.c.6533110.v1

Top 100%

0DataRank

Top 100%0 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more

Data from Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors

(2023)10.1158/1078-0432.c.6530489

N/A

0DataRank · unranked

0 citations

Karen A. Autio, Talia Golan, Konstantin Dobrenkov, Elliot Chartash, Qiusheng Chen +3 more

Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2886

N/A

0DataRank · unranked

57 citations

Karen A. Autio, Talia Golan, Konstantin Dobrenkov, Elliot Chartash, Qiusheng Chen +3 more

Georgina V. Long

Indexed papers

Top data-sharing exemplar

Papers